Concert Pharmaceuticals, Inc. (CNCE): Price and Financial Metrics

Concert Pharmaceuticals, Inc. (CNCE)

Today's Latest Price: $7.95 USD

0.07 (0.89%)

Updated Dec 10 4:00pm

Add CNCE to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 325 in Biotech

See all "A" rated Strong Buy stocks

CNCE Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CNCE is 0 -- better than only 7.05% of US stocks.
  • With a price/sales ratio of 6,336.7, Concert Pharmaceuticals Inc has a higher such ratio than 99.95% of stocks in our set.
  • As for revenue growth, note that CNCE's revenue has grown -99.98% over the past 12 months; that beats the revenue growth of only 0.44% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Concert Pharmaceuticals Inc are SAGE, TGTX, VHC, CBMG, and ZYNE.
  • CNCE's SEC filings can be seen here. And to visit Concert Pharmaceuticals Inc's official web site, go to
CNCE Daily Price Range
CNCE 52-Week Price Range

CNCE Stock Price Chart More Charts

CNCE Price/Volume Stats

Current price $7.95 52-week high $17.83
Prev. close $7.88 52-week low $5.36
Day low $7.73 Volume 128,800
Day high $7.98 Avg. volume 218,466
50-day MA $6.59 Dividend yield N/A
200-day MA $10.22 Market Cap 189.54M

Concert Pharmaceuticals, Inc. (CNCE) Company Bio

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform (deuterated chemical entity platform) to create novel small molecule drugs. The company was founded in 2006 and is based in Lexington, Massachusetts.

CNCE Latest News Stream

Event/Time News Detail
Loading, please wait...

CNCE Latest Social Stream

Loading social stream, please wait...

View Full CNCE Social Stream

CNCE Price Returns

1-mo 18.13%
3-mo -27.66%
6-mo -27.86%
1-year -36.95%
3-year -10.87%
5-year -28.95%
YTD -36.65%
2018 -51.49%
2017 151.41%
2016 -45.76%
2015 42.42%
2014 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6359 seconds.